aagami case study - assessment of global net present value (npv) of a revolutionary nanotechnology...

1

Click here to load reader

Upload: godwyn-francis

Post on 23-Jun-2015

156 views

Category:

Business


2 download

TRANSCRIPT

Page 1: Aagami Case Study - Assessment of Global Net Present Value (NPV) of a revolutionary Nanotechnology Based Diagnostic Platform

CaseStudy

Client

Client Need

Solution Approach

Results

**Data has been sanitized and meant for Illustrative purposes only

Global NPV of Technology (in USD Million)

(P) Pessimistic Scenario

Discount rate 8.60%

Year 2012 2013 2014 2015 2016 2017 2018

Time 0 1 2 3 4 5 6

Revenue from Sale of NPTP POC devices - - 20.30 23.62 32.06 40.80 24.93

Revenue from Sale of Treated Cuvette - - 450.00 614.87 815.48 1,021.15 657.19

Total Cost of NPTP POC devices - - 4.10 5.66 7.69 9.78 5.98

Total Cost of Treated Cuvettes - - 175.00 387.88 514.43 644.17 414.57

Commercialisation Costs 400.00 - - - - - -

Total Cash Inflow - - 470.30 638.49 847.54 1,061.96 682.11

Total cash Outflow 400.00 - 179.10 393.54 522.12 653.96 420.55

Net Cash Flow -400.00 - 291.20 244.95 325.43 408.00 261.56

Discount Factor 1.00 0.92 0.85 0.78 0.72 0.66 0.61

Discounted Cash Flow -400.00 - 246.91 191.24 233.96 270.09 159.44

NPV 1,524.77

Client wanted to commercialize ground breaking technology in the MI Diagnostics field, and wanted to know its commercial potential so that suitable licensing fees and model could be determined and also value could be showcased to Licensees

Investors Controlled Innovative technology company

Aagami involved a team of a senior consultant part time and a business analyst full time to conduct primary and secondary research involving domain specialists to capture current market scenario.

Performed competitive benchmarking to assess a Relative Cost Benefit Index used later for determining technology platform (product) pricing.

Projected annual demand for next ten years in three different scenarios - Median, Optimistic and Pessimistic across multiple disease categories.

Forecasted Global Average Selling Price (ASP) and Cost associated with capex and opex

Validated commercializing options and measured incremental financial scenario for potential licensees

Determined the Global Net Present Value (NPV) and created Financial models

NPV of the technology and indicative licensing fees, along with several insights generated, served as conclusive guidance to the client for deal-making and negotiations.

The client was delighted which also resulted in repeat assignments